When a bobcat was discovered by a motorist in January by the side of the highway after being hit by a car, her prognosis was grim. She was dehydrated, skinny and suffering from a leg fracture that had left her femur shattered into pieces.
Last week, less than six months after her ordeal began, she was released back into the Oregon wilderness—and it was all thanks to some big-hearted veterinarians and a donation from DePuy Synthes.
Repairing a Natural Born Runner
The bobcat was taken to Oregon State University’s College of Veterinary Medicine, where she was examined by Dr. Jennifer Warnock, Associate Professor of Small Animal Surgery.
“This was no house cat,” recalls Dr. Warnock. “Bobcats have to run many square miles every day, and hunt for a living. She is the ultimate athlete in the most unforgivable environment, so that femur had to be 150%.”
After determining the bobcat was a candidate for surgery, Warnock and her team used a DePuy Synthes plate and screws for the complex surgery to repair the big cat’s leg. The medical devices were provided through a donation to Oregon State by the DePuy Synthes Vet team. read more
Merck Commits €1.5 million to the Grant for Fertility Innovation (GFI) for 2016/17
Investment reflects company’s commitment to innovation in fertility research Globally, six projects receive funding from this grant cycle Darmstadt, Germany, July 6, 2016 – Merck, a leading science and technology company, today announced it would continue to support the advancement of medical science in the field of fertility through the Grant for Fertility Innovation (GFI) program by awarding grants totalling €1.5 million in 2016/17. The announcement was made at the 32nd annual meeting of European Society of Human Reproduction and Embryology (ESHRE), currently taking place in Helsinki, Finland.
NeuroVive announces Arbutus Biopharma’s notice of termination
Lund, Sweden, July 6, 2016 – NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that Arbutus Biopharma (formerly OnCore Biopharma, Inc.) has given NeuroVive a purported notice of termination of the license agreement signed in 2014, related to the development and commercialization of NeuroVive’s compound NVP018 for oral treatment of HBV. Arbutus’ notice, which NeuroVive questions on several grounds and in respect of which NeuroVive has reserved its rights, is a consequence of Arbutus’s decision to discontinue development of OCB-030 (NVP018), as communicated in October 2015. The fate of the license remains under discussion between the parties,